- Home
- SST vs ALXO Comparison
SST vs ALXO Comparison
Compare SST & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 68.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SST | ALXO |
|---|---|---|
| Price | $4.50 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $3.30 |
| AVG Volume (30 Days) | 21.5K | ★ 186.5K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.40 |
| 52 Week High | $15.00 | $2.27 |
Technical Indicators
Market Signals| Indicator | SST | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 54.61 |
| Support Level | $4.45 | $1.07 |
| Resistance Level | $4.75 | $1.18 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 94.19 | 69.57 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.